Sunitinib for Treatment of Advanced Renal Cell Cancer: Primary Tumor Response
Astrid A.M. van der Veldt(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), Epie Boven(Amsterdam UMC Location Vrije Universiteit Amsterdam), Martijn R. Meijerink(Dutch Cancer Society), Alfons J.M. van den Eertwegh(Amsterdam University Medical Centers), Gijsbert C. de Gast(The Netherlands Cancer Institute), Axel Bex(Royal Free London NHS Foundation Trust), John B.A.G. Haanen(B. J. Medical College & Sassoon Hospital)
Cited by 170
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
|The Lancet Oncology|2014|978
Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma
|Journal of Clinical Oncology|2013|799